Background--Our aim was to calibrate and externally revalidate the ELAN-HF (European Collaboration on Acute Decompensated Heart Failure) score, to confirm and improve on a previous external validation of the risk score.
and it is well established that patients with ADHF differ from one another substantially on their risk estimate. [5] [6] [7] A reliable risk stratification before discharge from the hospital may be used to further intensify therapies or intensify follow-up of those patients at higher risk and, in addition, provides extra information to the clinician as a performance measure. 7 To be usefully applied in the clinic, prognostic scores/models must be robust, simply applicable, and generalizable. The ELAN-HF (European Collaboration on Acute Decompensated Heart Failure) score is such a bedside score, predicting 6-month all-cause mortality in patients after hospitalization for ADHF. 8 This easy-to-use score offers several promising applications for clinical use as it does not exclude any particular ADHF population. 8 The 2017 American
College of Cardiology/American Heart Association/Heart Failure Society of America focused update of the 2013 guideline for heart failure recommends that "during a HF hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis," for which the ELAN-HF score has been cited. 9 The score has been validated previously in an external cohort, 10 which confirmed the predictive proportionality of the model. 8 However, in the original article, we did not calibrate the score and there were limitations about the validation cohort. 8 First, although discharge NT-proBNP (N-terminal pro-B-type natriuretic peptide) values were available in all patients, the NT-proBNP values at admission were not available; therefore, NT-proBNP values obtained 3 days before discharge were used as a proxy to calculate the change of NTproBNP during hospitalization. 8, 10 Second, assuming similar hazard ratios for NT-proBNP categories and other variables for shorter and longer follow-up durations, the follow-up duration of the validation cohort was extended to 1 year because of the small sample size, whereas the follow-up in the derivation cohort was 6 months after discharge. 8, 10 Therefore, the purpose of this study was to calibrate and revalidate the ELAN-HF score 8 in the recently published PRIMA II (Can NT-proBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?) trial cohort, a multicenter, international, randomized, controlled, 2-arm trial that aimed to study the effect of in-hospital guidance of ADHF treatment by a predefined NT-proBNP target. 11 Results of the PRIMA II trial were not different between the 2 treatment arms, and both treatment arms were included in the validation cohort.
Methods

Source/Study Populations
The ELAN-HF score was developed from 7 prospective cohorts of patients hospitalized for ADHF. The selection of the risk markers and construction of the model has been published previously. 8 Briefly, the score was developed using the multivariable Cox regression model, and variables were selected on the basis of the strongest predicting value for 6-month mortality after discharge. Thereafter, a simplified model was constructed by assigning weights to individual risk markers proportional to their regression coefficients. 8 The ELAN-HF score consisted of the following variables: absolute NT-proBNP levels at discharge of 1500 to 5000 pg/mL (1 point), 5001 to 15 000 pg/mL (3 points), and >15 000 pg/ mL (4 points). Other risk markers (1 point each) were as follows: NT-proBNP reduction of ≤30% from admission to discharge, aged ≥75 years at admission, presence of peripheral edema at admission, systolic blood pressure ≤115 mm Hg at admission, hyponatremia (sodium <135 mmol/L) at admission, serum urea of ≥15 mmol/L at discharge, and New York Heart Association class III or IV at discharge. The risk groups were categorized in the following manner: low (≤2 points), intermediate (3-4 points), high (5-7 points), and very high (≥8 points). 8 To perform an external validation, we used the cohort of the PRIMA II trial, an investigator-initiated, multicenter, randomized, prospective, 2-arm trial with either NT-proBNPguided therapy or conventional therapy for patients with ADHF. 11 The design and study population and the primary outcomes of the trial were reported previously. 11, 12 Briefly, patients admitted for ADHF (either de novo or acute-onchronic HF) and with NT-proBNP levels of ≥1700 pg/mL measured within 24 hours of hospital admission were eligible for the PRIMA II trial. 11, 12 From NT-proBNP measurements that were performed during hospitalization, we used only
Clinical Perspective
What Is New?
• This external validation study of the ELAN-HF (European Collaboration on Acute Decompensated Heart Failure) score confirms the excellent predictive proportional value of the risk score and shows that 6-month mortality increases with increasing score.
What Are the Clinical Implications?
• The ELAN-HF score is a statistically robust risk score predicting 6-month all-cause mortality in patients after hospitalization for acute decompensated heart failure, using NT-proBNP (N-terminal pro-B-type natriuretic peptide) values in addition to easily obtained clinical and laboratory characteristics, making it an easy to use and reliable bedside score to be used in the clinic practice.
admission and discharge NT-proBNP measurements. Followup visits for event registration were performed after discharge at 1 week and at 1, 3, and 6 months, where event registration was performed. The primary end point was a composite end point of all-cause mortality and readmission for HF at 6 months. 11, 12 Results of the PRIMA-II trial were not different between the 2 treatment arms, and both treatment arms were included in the validation cohort. Both trials (ELAN-HF and PRIMA-II) were approved by the institutional review committees in their respective centers, and all subjects gave informed consent. 8, 11, 12 The data that support the findings of this study are available from the corresponding author to other researchers for purposes of reproducing the results or replicating the procedure on reasonable request, ensuring data deidentification.
Statistical Analysis
The primary end point for model calibration and discrimination was all-cause mortality at 6 months. Demographic characteristics were published previously. 8, 11 We compared the baseline demographics and clinical characteristics between the derivation and validation cohorts using the Fisher exact test to make a comparison for categorical data and the independent t test to make a comparison for normally distributed continuous variables; the independent-sample Mann-Whitney U test was used to make a comparison for all other continuous variables. The distribution of ELAN-HF score predictors in the derivation and validation data sets is presented as frequencies and percentages.
To assess the discriminatory accuracy of our model, we calculated 6-month mortality in the validation cohort (PRIMA II) by the Kaplan-Meier method (Kaplan-Meier curves) with logrank test for each of the 4 categories of the ELAN-HF risk score. To calculate the ELAN-HF score, each variable in the multivariate model was multiplied by its regression coefficient 8 ; and the products were summed and prospectively applied to each patient in both the derivation cohort as well as in the validation cohort to provide individual estimates of survival at 6 months. 13, 14 First, the baseline survival function (B 0 ) was estimated at the observed time of 6 months in the derivation cohort (B 0 =0.983). For a given value of the ELAN-HF score, we calculated the predicted mortality function (M pred ) in the derivation and validation data sets by the following equation 13 :
Thereafter, calibration was assessed by calculating the actual mortality using Kaplan-Meier curves and the expected mortality in each risk group by calculating the mean predicted mortality at 6 months over all members of each aforementioned risk group in both the derivation (ELAN-HF) and the validation (PRIMA II) cohorts. Moreover, to further asses the accuracy of the calibration of our model, we also plotted the mean predicted mortality against the observed mortality (Kaplan-Meier) by deciles of predicted mortality for the derivation cohort and by quintiles (because of the smaller sample size) of predicted mortality for the validation cohort. 14 Calibration was assessed by a correlation coefficient and SEE. The model discriminant ability was determined by the 6-month receiver-operating characteristic area under the curve for both data sets, using the categorized model. We used the method of Hanley and MacNeil to compare the Cstatistics. 15 To accommodate for the different cohorts, separate baseline hazard functions were used to adjust for betweenstudy differences. For the multivariable model, we performed multiple imputation pooling algorithms (n=10) to correct for missing values using predictive mean matching. All patient, medical history, and treatment variables (including outcome variables) were used when creating the multiple imputation data sets. All probability values were 2 sided and considered significant if P<0.05. Statistical analyses were conducted using SPSS 24.0.0.0 (SPSS IBM, New York, NY).
Results
Demographic Characteristics
The detailed demographics table for both the derivation cohort as well as for the validation cohort has been reported previously in the original articles. 8, 11 Briefly (Table S1 ), the patients in the PRIMA II (validation) cohort were older than those in the ELAN-HF (derivation) cohort (77 versus 74 years; P<0.001), with more female patients (51% versus 40%; P<0.001) and patients more frequently with hypertension (64% versus 51%; P<0.001), peripheral edema (73% versus 62%; P<0.001), and a higher mean systolic blood pressure at admission (137 versus 133 mm Hg; P=0.028) and fewer patients admitted with New York Heart Association class III/IV (79% versus 96%; P<0.001). For routine laboratory measurements, patients in the validation cohort had significantly lower mean levels of urea nitrogen at admission (12 versus 13 mmol/L; P=0.024), lower serum sodium levels at admission (138 versus 139 mmol/L; P=0.005), and lower estimated glomerular filtration rate levels at admission (52 versus 57 mL/min per 1.73 m 2 ; P=0.002).
There was no significant difference between validation and derivation cohorts for median NT-proBNP level at admission (6182 versus 6447 pg/mL; P=0.433) as well as at discharge (2910 versus 3252 pg/mL; P=0.096). The median NT-proBNP reduction percentage during hospitalization was significantly higher for the validation cohort compared with the derivation cohort (47% versus 43%; P=0.007). At discharge, significantly fewer patients in the validation cohort received diuretics compared with patients in the derivation cohort (92% versus 95%; P=0.010), but more patients received b blockers (75% versus 57%; P<0.001).
The Distribution Predictors
The distribution of the predictors between the derivation and validation cohorts is shown in Table 1 . The distributions happen to be broadly similar between the derivation and validation data sets, although this is not a requirement for successful validation. 13 
Adverse Events
In both studies, no patients were lost to follow-up, and followup data were 100% complete. In the PRIMA II trial, 74 died of any cause within 6 months, which was equal to an all-cause mortality of 18%. In the ELAN-HF trial, 195 died of any cause within 6 months, which was equal to an all-cause mortality of 15% (P=0.118).
Calibration and Validation of the ELAN-HF Score Figure 1 shows Kaplan-Meier curves for 6-month all-cause mortality in the validation cohort, according to the 4 risk groups. The figure shows that the curves are increasing significantly in a stepwise manner across the risk groups, confirming our earlier conclusion that the model has excellent discriminatory ability. 8 The predicted and observed mortality rates in the derivation and the validation cohorts are presented in tabular (Table 2) form for the 4 risk groups.
The stepwise increase in all-cause mortality for the 4 risk groups for the derivation cohort increased with a rate of 3.6% for the low-risk patients, 9.2% for the patients with an intermediate risk, 23.5% for the patients with a high risk, and 51.1% for the very-high-risk patients. 8 This was in complete agreement with the results in the validation cohort, after the ELAN-HF model was applied prospectively to the validation cohort, with mortality rates in the 4 risk categories of 2.2%, 8.2%, 22.9%, and 53.6%, respectively. In the derivation cohort, the predicted 6-month mortality rates, according to the risk categories, were 3.6% for the low-risk category, 9.4% for the intermediate-risk category, 24.2% for the high-risk category, and 54.2% for the veryhigh-risk category; there was a correlation coefficient of 0.92, with a SEE of AE4%, between predicted and observed mortality by decile (Figure 2 ). In the validation cohort, predicted 6-month mortality rates, according to the risk categories, were 3.0%, 9.4%, 25.0%, and 56.8%, respectively; there was a correlation coefficient of 0.99, with a SEE of AE2%, between predicted and observed mortality by quintiles. Table 3 shows the 6-month receiver-operating characteristic for the derivation cohort was 0.78 (95% CI, 0.74-0.82). In the validation cohort, the 6-month receiver-operating characteristic was 0.77 (95% CI, 0.69-0.84), not different from the C-statistic of the derivation cohort (P=0.693).
ELAN-HF Score Discriminant Ability
Discussion
The ELAN-HF score is a bedside score predicting 6-month allcause mortality in patients after hospitalization for ADHF, for patients with both preserved ejection fraction and reduced ejection fraction, with a wide range of heart failure symptoms at discharge (New York Heart Association class I to IV). 8 The ELAN-HF score was previously validated in an external cohort. 8, 10 However, because of limitations of the validation data set, we set out to calibrate and revalidate the ELAN-HF score prospectively in the PRIMA II cohort. 11 Our data show that the score is statistically robust in that both the calibration and external validity of the risk score were confirmed in the validation cohort using 4 risk categories. The model shows an excellent predictive proportional value and confirms the increasing 6-month mortality with increasing score using NT-proBNP values in addition to easily obtained clinical and laboratory characteristics.
Revalidating the ELAN-HF Score
External validation is a crucial step toward acceptance of a risk score into clinical practice. If a prognostic model predicts outcome well on a derivation cohort, but weakly on an independent cohort, it is clearly not fit for use. There are 2 fundamental aspects of validating model performance: discrimination and calibration. 13 Discrimination is the ability of a model to predict that patients at higher risk should exhibit higher event rates than those at lower risk. Calibration reflects the prediction accuracy, where the correct event probability is assigned at all levels of predicted risk, without underpredicting or overpredicting the event probability. 13 The ELAN-HF score performs excellent on both departments. The model shows an excellent discriminative proportional value and confirms the increasing 6-month mortality with increasing score. Furthermore, our data showed that the calibration is excellent for the 4 risk categories for both data sets. The observed and predicted all-cause mortality rates in the 2 data sets are almost identical, reflecting the similarity in the distributions of the ELAN-HF score in each risk group across the data sets. In our previous study, 8 we only performed the external validation with level 2 information available. 13 With this study, we were able to externally validate the risk score with level 3 information available, 13 which shows that it is a reliable risk score to be used in the clinic practice.
Discriminative Ability
The risk score performed as well in the derivation cohort (ELAN-HF) as in the validation cohort (PRIMA II), as evidenced by the C-statistics. There was no difference between the Cstatistics, with values of the C-statistic of 0.76 (95% CI, 0.71-0.80) and 0.77 (95% CI, 0.69-0.84) for the derivation and validation cohorts, respectively. The strength of the ELAN-HF model is its broad applicability and its easy calculation. Moreover, variables in the model can be easily ascertained when a patient has been hospitalized for ADHF.
Other Risk-Predicting Models for Patients With ADHF, Using Natriuretic Peptide Levels
The OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) study showed that a model using clinical variables plus discharge BNP appropriately reclassifies risk in tertiles of 1-year mortality in a mixed population of patients with ADHF, aged ≥65 years, and improves discrimination compared with a model with clinical variables alone, with a final C-statistic of 0.69. 16 Calibration of the model was done; however, the model was not externally validated. 16 ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) was used to derive a clinical model, including natriuretic peptides (BNP) at discharge, with a C-index of 0.76 for predicting 6-month mortality. 17 The patient population consisted of patients with severe left systolic heart failure. The model was externally validated with clinical variables only, although BNP levels were the most important prognostic variable. 17 The COACH (Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure) risk engine was previously published, using clinical and laboratory variables and discharge NT-proBNP levels, in a mixed population with ADHF, similar to our populations with ADHF. From a multistate model, the COACH risk engine predicts 18-month mortality and/or hospital readmissions for heart failure. 18 Their C-index for mortality was 0.73 in the derivation cohort and (with 48-hour NTproBNP levels in place of discharge levels) was 0.70 in the validation cohort. 18 The prediction is for 18 months, which may make it less useful for earlier assessments, as risk weans off with time and other risk predictors may come into play. The program can be downloaded from the internet, which makes its clinical use more convenient. The ADHF/NTproBNP risk score for 1-year mortality, heart transplantation, or left ventricular assist device implantation, in patients with ADHF with left ventricular ejection fraction ≤40% well treated with an implantable cardioverter defibrillator and a cardiac resynchronization therapy defibrillator, performs well, with a C-statistic of 0.84 in the derivation cohort and 0.77 in the validation cohort. 19 Apart from its selected population, a critique may be the use of admission NT-proBNP levels, which have lower predictive ability than discharge NT-proBNP levels, although their contribution to the final risk assessment was high in this particular score. 19 The more recent risk models, such as the BIOSTAT-CHF (A Systems Biology Study to Tailored Treatment in Chronic Heart Failure), include patients after discharge as well as patients at the outpatient clinic, necessitating the incorporation of having been hospitalized for heart failure as an added risk variable, which was also externally validated. 20 However, the C-statistic for the compact model was lower compared with the C-statistic of our simple bedside model (0.69 versus 0.76), possibly because of the interference of the outpatient population.
Limitations
The derivation cohort was an individual patient data analysis of 7 cohorts, which was conceived after publication of the original studies. 8 Apart from some variation in NT-proBNP assays used, treatment and inclusion criteria in the different centers should be considered. Nevertheless, the range in markers and therapeutic approach of patients, as observed, reflects the day-to-day clinical practice. Missing data should be considered as a limitation in our study. However, we did correct for the bias from data missing at random by using multiple imputation pooling algorithms. Furthermore, the use of all-cause mortality instead of cardiovascular mortality as the primary outcome is a limitation. It is, however, clear that cardiovascular mortality explains 63% to 87% of mortality after ADHF.
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Conclusions
External validation of the ELAN-HF risk score in the PRIMA II cohort confirms its excellent accuracy and discriminative ability. The score allows accurate prediction of 6-month mortality of patients hospitalized for ADHF with the use of easily obtained clinical and laboratory characteristics, including absolute natriuretic peptide levels at discharge and a relative change in natriuretic peptide of ≤30% from admission values. The risk stratification, as predicted in our bedside model, is in complete agreement with that in the external validation cohort, which shows that it is a reliable score to be used in the clinic practice.
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